Novel use of zolpidem in cerebellar mutism syndrome Journal Article


Authors: Shyu, C.; Burke, K.; Souweidane, M. M.; Dunkel, I. J.; Gilheeney, S. W.; Gershon, T.; Khakoo, Y.
Article Title: Novel use of zolpidem in cerebellar mutism syndrome
Abstract: Cerebellar mutism syndrome (CMS) is a complication of posterior fossa surgery seen primarily in pediatric patients after resection of medulloblastoma. CMS is characterized by mutism, ataxia, hypotonia, and irritability. Currently, there is no therapy of proven efficacy. Zolpidem, although primarily used as a sedative, has been shown to alleviate mutism and promote arousal in similar neurologic and psychiatric disorders. Here, we describe a child with severe CMS in whom zolpidem seemed to increase arousal, accelerate the resolution of mutism, and decrease emotional lability. Our report suggests that clinicians should consider using zolpidem for patients with CMS. Copyright © 2011 by Lippincott Williams & Wilkins.
Keywords: child; treatment response; child, preschool; case report; pyridines; nuclear magnetic resonance imaging; bedtime dosage; postoperative complication; postoperative complications; insomnia; disease severity; medulloblastoma; left hemisphere; cerebellar neoplasms; irritability; ataxia; brain surgery; neurosurgical procedures; mental instability; zolpidem; arousal; cerebellar mutism syndrome; posterior fossa syndrome; cerebellar diseases; gaba-a receptor agonists; mutism
Journal Title: Journal of Pediatric Hematology/Oncology
Volume: 33
Issue: 2
ISSN: 1077-4114
Publisher: Lippincott Williams & Wilkins  
Date Published: 2011-03-01
Start Page: 148
End Page: 149
Language: English
DOI: 10.1097/MPH.0b013e3182053a1a
PUBMED: 21285896
PROVIDER: scopus
DOI/URL:
Notes: --- - "Export Date: 23 June 2011" - "CODEN: JPHOF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ira J Dunkel
    371 Dunkel
  2. Yasmin Khakoo
    149 Khakoo
  3. Kelly Burke
    1 Burke